Clinical significance of fecal Syndecan-2 gene methylation combined with blood tumor abnormal protein detection in the diagnosis of colorectal cancer and precancerous lesions.

IF 2.5 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinical biochemistry Pub Date : 2025-01-18 DOI:10.1016/j.clinbiochem.2025.110887

Xuanjun Liu, Guowei Zhao, Weixu Mao, Qigang Li, Juan Liao, Gan He

{"title":"Clinical significance of fecal Syndecan-2 gene methylation combined with blood tumor abnormal protein detection in the diagnosis of colorectal cancer and precancerous lesions.","authors":"Xuanjun Liu, Guowei Zhao, Weixu Mao, Qigang Li, Juan Liao, Gan He","doi":"10.1016/j.clinbiochem.2025.110887","DOIUrl":null,"url":null,"abstract":"Objective: To investigate the clinical significance of fecal Syndecan-2 (SDC2) gene methylation combined with blood tumor abnormal protein (TAP) detection for the diagnosis of colorectal cancer (CRC) and its precancerous lesions.Methods: A retrospective study was conducted to collect patients diagnosed with CRC or colorectal adenoma (Ade) from March 2020 to March 2023, and healthy people (Nor) without any gastrointestinal diseases during the same period as the control group. All participants underwent the fecal SDC2 gene methylation test, blood TAP test and fecal occult blood test (FOBT). The differences in the positivity rates of each index were compared, receiver operator characteristic curves were plotted and the area under the curve (AUC) was calculated to evaluate the diagnostic effects of different testing methods on CRC and its precancerous lesions.Results: A total of 146 individuals were included in the study, including 69 CRC patients, 47 patients with Ade and 30 healthy individuals. The results showed that, SDC2, TAP and the combined assay had high comprehensive diagnostic efficacy for the diagnosis of CRC, but there was no significant difference between the three methods in terms of AUC, sensitivity, and specificity. However, for Ade, the combined detection was statistically significant, with a high AUC (0.905), high sensitivity (95.7%), and high specificity (86.7%).Conclusion: Fecal SDC2 gene methylation combined with blood TAP detection is an effective noninvasive screening and diagnostic method to enhance the early detection and treatment of CRC precancerous lesions, such as Ade, thereby reducing the incidence and mortality of CRC.","PeriodicalId":10172,"journal":{"name":"Clinical biochemistry","volume":" ","pages":"110887"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinbiochem.2025.110887","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To investigate the clinical significance of fecal Syndecan-2 (SDC2) gene methylation combined with blood tumor abnormal protein (TAP) detection for the diagnosis of colorectal cancer (CRC) and its precancerous lesions.

Methods: A retrospective study was conducted to collect patients diagnosed with CRC or colorectal adenoma (Ade) from March 2020 to March 2023, and healthy people (Nor) without any gastrointestinal diseases during the same period as the control group. All participants underwent the fecal SDC2 gene methylation test, blood TAP test and fecal occult blood test (FOBT). The differences in the positivity rates of each index were compared, receiver operator characteristic curves were plotted and the area under the curve (AUC) was calculated to evaluate the diagnostic effects of different testing methods on CRC and its precancerous lesions.

Results: A total of 146 individuals were included in the study, including 69 CRC patients, 47 patients with Ade and 30 healthy individuals. The results showed that, SDC2, TAP and the combined assay had high comprehensive diagnostic efficacy for the diagnosis of CRC, but there was no significant difference between the three methods in terms of AUC, sensitivity, and specificity. However, for Ade, the combined detection was statistically significant, with a high AUC (0.905), high sensitivity (95.7%), and high specificity (86.7%).

Conclusion: Fecal SDC2 gene methylation combined with blood TAP detection is an effective noninvasive screening and diagnostic method to enhance the early detection and treatment of CRC precancerous lesions, such as Ade, thereby reducing the incidence and mortality of CRC.

查看原文本刊更多论文

粪便Syndecan-2基因甲基化联合血液肿瘤异常蛋白检测在结直肠癌及癌前病变诊断中的临床意义

目的：探讨粪便Syndecan-2 （SDC2）基因甲基化联合血液肿瘤异常蛋白（TAP）检测在结直肠癌（CRC）及其癌前病变诊断中的临床意义。方法：回顾性研究收集2020年3月至2023年3月诊断为结直肠癌或结直肠腺瘤（Ade）的患者，以及同期无胃肠道疾病的健康人群（Nor）作为对照组。所有参与者都进行了粪便SDC2基因甲基化测试、血液TAP测试和粪便潜血测试（FOBT）。比较各指标阳性率的差异，绘制受试者操作者特征曲线，计算曲线下面积（AUC），评价不同检测方法对结直肠癌及其癌前病变的诊断效果。结果：共纳入146例，其中CRC患者69例，Ade患者47例，健康个体30例。结果显示，SDC2、TAP及联合检测对结直肠癌的诊断具有较高的综合诊断效能，但三种方法在AUC、敏感性、特异性方面无显著差异。然而，对于Ade，联合检测具有统计学意义，具有高AUC(0.905)，高灵敏度（95.7%）和高特异性（86.7%）。结论：粪便SDC2基因甲基化联合血液TAP检测是一种有效的无创筛查和诊断方法，可提高对Ade等结直肠癌癌前病变的早期发现和治疗，从而降低结直肠癌的发病率和死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical biochemistry 医学-医学实验技术

CiteScore

5.10

自引率

0.00%

发文量

151

审稿时长

25 days

期刊介绍： Clinical Biochemistry publishes articles relating to clinical chemistry, molecular biology and genetics, therapeutic drug monitoring and toxicology, laboratory immunology and laboratory medicine in general, with the focus on analytical and clinical investigation of laboratory tests in humans used for diagnosis, prognosis, treatment and therapy, and monitoring of disease.